ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Altimmune, Inc. (ALT) stock declined over -2.87%, trading at $4.40 on NASDAQ, down from the previous close of $4.53. The stock opened at $4.46, fluctuating between $4.32 and $4.52 in the recent session.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Employees | 59 |
Beta | 0.89 |
Sales or Revenue | $426.00K |
5Y Sales Change% | -0.998% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |